{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:04:36Z","timestamp":1790741076950,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pathol.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:20:59Z","timestamp":1719937259000},"page":"982-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Laboratory validation and clinical utility of next-generation sequencing-based IGH\/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-7600","authenticated-orcid":false,"given":"Stephen B.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Gorniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-103X","authenticated-orcid":false,"given":"Chun Y.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-0403","authenticated-orcid":false,"given":"Rishu","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2024.04.012_bib1","series-title":"Cancer data in Australia. Blood cancer incidence and survival by histology","year":"2023"},{"key":"10.1016\/j.pathol.2024.04.012_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2024.04.012_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2024.04.012_bib4","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Haematolymphoid Tumours. 5th ed, Vol. 11. Beta version 2 ahead of print; cited 26 Nov 2023. Lyon: IARC, 2022. https:\/\/tumourclassification.iarc.who.int\/chapters\/63"},{"key":"10.1016\/j.pathol.2024.04.012_bib5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2024.04.012_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.17879","article-title":"B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification","volume":"197","author":"Yeung","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2024.04.012_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.pathol.2024.04.012_bib8","article-title":"Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia","volume":"43","author":"Dekker","year":"2023","journal-title":"Am Soc Clin Oncol Edu Book"},{"key":"10.1016\/j.pathol.2024.04.012_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2024.04.012_bib10","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2024.04.012_bib11","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing\u2013based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2024.04.012_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.pathol.2024.04.012_bib13","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2024.04.012_bib14","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1002\/cpz1.383","article-title":"Measurable residual disease detection in B-acute lymphoblastic leukemia: the Children\u2019s Oncology Group (COG) Method","volume":"2","author":"Borowitz","year":"2022","journal-title":"Curr Protoc"},{"key":"10.1016\/j.pathol.2024.04.012_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jmoldx.2018.03.002","article-title":"Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult philadelphia-positive acute lymphoblastic leukemia","volume":"20","author":"Coccaro","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.pathol.2024.04.012_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jmoldx.2021.07.008","article-title":"Comparison of two quantitative PCR\u2013based assays for detection of minimal residual disease in B-precursor acute lymphoblastic leukemia harboring three major fusion transcripts","volume":"23","author":"Huang","year":"2021","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.pathol.2024.04.012_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","article-title":"MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR","volume":"538","author":"van der Velden","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.pathol.2024.04.012_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-0716-2115-8_3","article-title":"One-step next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia","volume":"2453","author":"Villarese","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.pathol.2024.04.012_bib19","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2024.04.012_bib20","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2024.04.012_bib21","first-page":"138","article-title":"Evaluation of minimal residual disease (MRD) and MRD-based treatment decisions in Ph\/BCR-ABL negative adult acute lymphoblastic leukemia (ALL): experience from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"130","author":"Goekbuget","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib22","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2024.04.012_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2022-158381","article-title":"Results of the risk-adapted, MRD-stratified GMALL trial 08\/2013 in 281 T-ALL\/T-Lbl patients: excellent outcome of standard risk thymic T-ALL","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O\u2019Connor","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2024.04.012_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2024.04.012_bib26","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A\u00a0pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib27","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib28","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib29","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2024.04.012_bib31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.pathol.2024.04.012_bib32","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/s41467-023-43171-9","article-title":"Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2024.04.012_bib33","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2024.04.012_bib34","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2024.04.012_bib35","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1182\/blood.V87.11.4789.bloodjournal87114789","article-title":"Persistence of multipotent progenitors expressing AML1\/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia","volume":"87","author":"Miyamoto","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2024.04.012_bib37","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2024.04.012_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cytob.21195","article-title":"Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a French multicenter study","volume":"88","author":"Fossat","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.pathol.2024.04.012_bib39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41375-019-0599-1","article-title":"Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia","volume":"34","author":"Kotrova","year":"2020","journal-title":"Leukemia"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T17:06:52Z","timestamp":1730826412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302524001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0031302524001715"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2024.04.012","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory validation and clinical utility of next-generation sequencing-based IGH\/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}